These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 27421122)

  • 1. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Papanikolaou V; Akriviadis E
    Transpl Int; 2014 Oct; 27(10):1022-8. PubMed ID: 24909714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
    Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Goulis J; Akriviadis E; Papatheodoridis GV
    Liver Transpl; 2011 Oct; 17(10):1176-90. PubMed ID: 21656655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Papatheodoridis GV
    Am J Transplant; 2013 Feb; 13(2):353-62. PubMed ID: 23137006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
    Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
    Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liver transplantation for complications of hepatitis B].
    Roche B; Samuel D
    Presse Med; 2006 Feb; 35(2 Pt 2):335-45. PubMed ID: 16493338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.
    Lenci I; Tisone G; Di Paolo D; Marcuccilli F; Tariciotti L; Ciotti M; Svicher V; Perno CF; Angelico M
    J Hepatol; 2011 Sep; 55(3):587-593. PubMed ID: 21251938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Patterson SJ; Angus PW
    Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
    McGonigal KH; Bajjoka IE; Abouljoud MS
    Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.